Granahan Investment Management - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 44 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Granahan Investment Management ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q2 2019$1,336,000
-34.9%
804,964
-2.0%
0.07%
-40.0%
Q1 2019$2,053,000
-12.6%
821,116
-11.2%
0.11%
-33.7%
Q4 2018$2,348,000
-50.6%
924,300
-1.8%
0.17%
-35.7%
Q3 2018$4,753,000
+59.3%
941,170
+2.8%
0.26%
+43.3%
Q2 2018$2,984,000
+2.7%
915,449
+14.1%
0.18%
-14.3%
Q1 2018$2,905,000
+199.8%
802,521
+68.1%
0.21%
+176.3%
Q4 2017$969,000
+36.9%
477,438
+14.6%
0.08%
+28.8%
Q3 2017$708,000
+276.6%
416,608
+488.3%
0.06%
+247.1%
Q2 2017$188,000
-17.5%
70,810
+114.5%
0.02%
-26.1%
Q1 2017$228,00033,0100.02%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2018
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 1,689,064$5,506,0003.35%
PERKINS CAPITAL MANAGEMENT INC 249,700$814,0000.58%
Private Wealth Partners, LLC 900,000$2,934,0000.49%
Diametric Capital, LP 60,752$198,0000.19%
Granahan Investment Management 915,449$2,984,0000.18%
B. Riley Wealth Advisors, Inc. 250,000$815,0000.11%
Kalos Management, Inc. 38,000$137,0000.06%
Spark Investment Management LLC 203,600$663,0000.04%
GSA CAPITAL PARTNERS LLP 199,500$650,0000.03%
Crow Point Partners, LLC 25,860$84,0000.02%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders